SRR8392881
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.320
- G2M_CHECKPOINT+0.300
- OXIDATIVE_PHOSPHORYLATION+0.260
- SPERMATOGENESIS+0.190
- CHOLESTEROL_HOMEOSTASIS+0.110
- KRAS_SIGNALING_DN+0.080
- FATTY_ACID_METABOLISM+0.070
- BILE_ACID_METABOLISM+0.020
- PEROXISOME+0.010
- PI3K_AKT_MTOR_SIGNALING+0.000
Top 10 suppressed
- ANGIOGENESIS-0.510
- MYC_TARGETS_V2-0.360
- TGF_BETA_SIGNALING-0.360
- GLYCOLYSIS-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- HYPOXIA-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.290
- WNT_BETA_CATENIN_SIGNALING-0.290
- HEDGEHOG_SIGNALING-0.260
- IL6_JAK_STAT3_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7385-01A-11R-2016-07 | — | — | 0.822 |
| 2 | TCGA-QK-A6V9-01A-11R-A34R-07 | — | — | 0.806 |
| 3 | TCGA-CN-5374-01A-01R-1436-07 | — | — | 0.795 |
| 4 | TCGA-CR-5248-01A-01R-2016-07 | — | — | 0.790 |
| 5 | TCGA-P3-A5Q5-01A-11R-A28V-07 | — | — | 0.784 |
| 6 | TCGA-CN-A49C-01A-11R-A24H-07 | — | — | 0.775 |
| 7 | R288 | — | — | 0.773 |
| 8 | TCGA-QK-AA3J-01A-11R-A39I-07 | — | — | 0.758 |
| 9 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.757 |
| 10 | SRR12202422 | — | — | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |